Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBIAT: 2013-2017

Historic EBIAT for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$4.7 million.

  • Soleno Therapeutics' EBIAT fell 81.50% to -$4.7 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$15.4 million, marking a year-over-year decrease of 27.52%. This contributed to the annual value of -$175.9 million for FY2024, which is 351.16% down from last year.
  • Soleno Therapeutics' EBIAT amounted to -$4.7 million in Q4 2017, which was down 25.28% from -$3.8 million recorded in Q3 2017.
  • Soleno Therapeutics' 5-year EBIAT high stood at $1.9 million for Q2 2015, and its period low was -$11.7 million during Q1 2015.
  • In the last 3 years, Soleno Therapeutics' EBIAT had a median value of -$3.2 million in 2015 and averaged -$3.6 million.
  • The largest annual percentage gain for Soleno Therapeutics' EBIAT in the last 5 years was 167.35% (2015), contrasted with its biggest fall of 1,297.00% (2015).
  • Soleno Therapeutics' EBIAT (Quarterly) stood at -$974,243 in 2013, then slumped by 640.95% to -$7.2 million in 2014, then skyrocketed by 60.59% to -$2.8 million in 2015, then climbed by 8.13% to -$2.6 million in 2016, then tumbled by 81.50% to -$4.7 million in 2017.
  • Its last three reported values are -$4.7 million in Q4 2017, -$3.8 million for Q3 2017, and -$4.0 million during Q2 2017.